Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

COVID19

COVID-19 Vaccines: AstraZeneca Resumes Trial; Pfizer, BioNTech Look to Expand Study

Diana Ernst, RPh

September 17, 2020

AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.

COVID19

Remdesivir EUA Expanded to Include All Hospitalized COVID-19 Patients

Diana Ernst, RPh

September 9, 2020

Previously, the EUA limited use to patients with severe COVID-19 disease.

Respiratory

ACIP: Influenza Vaccination Recommendations for 2020-2021

Diana Ernst, RPh

August 26, 2020

Influenza vaccination should occur by the end of October, if possible.

COVID19

Emergency Use Authorization Issued for COVID-19 Convalescent Plasma

Diana Ernst, RPh

August 25, 2020

The EUA was based on historical evidence indicating some effectiveness with convalescent plasma use in previous outbreaks of respiratory viruses, preclinical data, results from small clinical trials, and data from the National Expanded Access Treatment Protocol sponsored by the Mayo Clinic.

Genitourinary

Managing SGLT2 Inhibitor-Associated Genital Mycotic Infections

Diana Ernst, RPh

August 21, 2020

Genital mycotic infection is listed as a potential adverse effect of the SGLT2 inhibitor class.

COVID19

Pfizer, BioNTech Select COVID-19 Vaccine Candidate, Initiate Phase 2/3 Study

Diana Ernst, RPh

July 30, 2020

Pfizer and BioNTech have selected a coronavirus disease 2019 (COVID-19) vaccine candidate and have initiated their phase 2/3 safety and efficacy trial.

COVID19

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 9, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

COVID19

NIH: Trial Investigating Hydroxychloroquine for COVID-19 Stopped

Diana Ernst, RPh

June 26, 2020

A National Institutes of Health-led clinical trial evaluating hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) has been halted after a data and safety monitoring board determined that the drug was unlikely to benefit hospitalized patients.

COVID19

FDA: Coadministration of Remdesivir With CQ or HCQ Not Recommended

Diana Ernst, RPh

June 22, 2020

The antiviral activity of remdesivir, an investigational treatment for COVID-19, may potentially be reduced if it is coadministered with chloroquine or hydroxychloroquine, according to the FDA.

COVID19

FDA: Emergency Use Authorization Revoked for Chloroquine, Hydroxychloroquine

Diana Ernst, RPh

June 19, 2020

The FDA has revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate based on emerging data suggesting that these agents are unlikely to be effective against COVID-19.

Next post in COVID19